{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:17:05Z","timestamp":1777501025206,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["20FC1045"],"award-info":[{"award-number":["20FC1045"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s10157-023-02366-6","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T09:01:51Z","timestamp":1686646911000},"page":"767-775","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Japanese clinical practice patterns of primary nephrotic syndrome 2021: a web-based questionnaire survey of certified nephrologists"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9740-5183","authenticated-orcid":false,"given":"Takehiko","family":"Wada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayaka","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Sofue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Nishiwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izaya","family":"Nakaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Oe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Ishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Furuichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Kurita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"issue":"8","key":"2366_CR1","first-page":"751","volume":"44","author":"H Sakai","year":"2002","unstructured":"Sakai H, Kurokawa K, Saito T, Shiiki H, Nishi S, Mitarai T, et al. Guidelines for the management of refractory nephrotic syndrome\u2013from investigations between 1997 and 2001\u2013research project team for progressive renal lesions in the Ministry of Health, Labor and Welfare, Japan. Nihon Jinzo Gakkai Shi. 2002;44(8):751\u201361.","journal-title":"Nihon Jinzo Gakkai Shi"},{"issue":"3","key":"2366_CR2","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s10157-015-1216-x","volume":"20","author":"S Nishi","year":"2016","unstructured":"Nishi S, Ubara Y, Utsunomiya Y, Okada H, Obata Y, Kai H, et al. Evidence-based clinical practice guidelines for nephrotic syndrome 2014. Clin Exp Nephrol. 2016;20(3):342\u201370. https:\/\/doi.org\/10.1007\/s10157-015-1216-x.","journal-title":"Clin Exp Nephrol"},{"key":"2366_CR3","unstructured":"Maruyama S. Committee of Clinical Practice Guideline for Nephrotic Syndrome 2017, editors. Evedence-based clinical practice guideline for nephrotic syndrome 2017. Tokyo: Tokyo Igakusha. 2017. http:\/\/jin-shogai.jp\/policy\/pdf\/Neph_2017.pdf"},{"issue":"12","key":"2366_CR4","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s10157-021-02098-5","volume":"25","author":"T Wada","year":"2021","unstructured":"Wada T, Ishimoto T, Nakaya I, Kawaguchi T, Sofue T, Shimizu S, et al. A digest of the evidence-based clinical practice guideline for nephrotic syndrome 2020. Clin Exp Nephrol. 2021;25(12):1277\u201385. https:\/\/doi.org\/10.1007\/s10157-021-02098-5.","journal-title":"Clin Exp Nephrol"},{"key":"2366_CR5","unstructured":"Narita I. Committee of Clinical Practice Guideline for Nephrotic Syndrome 2020, editors. Evedence-based clinical practice guideline for nephrotic syndrome 2017. Tokyo: Tokyo Igakusha. 2020. http:\/\/jin-shogai.jp\/policy\/pdf\/Neph_2020.pdf"},{"key":"2366_CR6","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3233\/SHTI200154","volume":"270","author":"A Lamer","year":"2020","unstructured":"Lamer A, Laurent G, Pelayo S, El Amrani M, Chazard E, Marcilly R. Exploring patient path through Sankey diagram: a proof of concept. Stud Health Technol Inform. 2020;270:218\u201322. https:\/\/doi.org\/10.3233\/SHTI200154.","journal-title":"Stud Health Technol Inform"},{"issue":"8","key":"2366_CR7","doi-asserted-by":"publisher","first-page":"e104936","DOI":"10.1371\/journal.pone.0104936","volume":"9","author":"Y Du","year":"2014","unstructured":"Du Y, Li J, He F, Lv Y, Liu W, Wu P, et al. The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis. PLoS\u00a0One. 2014;9(8):e104936. https:\/\/doi.org\/10.1371\/journal.pone.0104936.","journal-title":"PLoS\u00a0One."},{"issue":"4S","key":"2366_CR8","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1-276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021.","journal-title":"Kidney Int"},{"issue":"1","key":"2366_CR9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/ndt\/gfp422","volume":"25","author":"A Eguchi","year":"2010","unstructured":"Eguchi A, Takei T, Yoshida T, Tsuchiya K, Nitta K. Combined cyclosporine and prednisolone therapy in adult patients with the first relapse of minimal-change nephrotic syndrome. Nephrol Dial Transplant. 2010;25(1):124\u20139. https:\/\/doi.org\/10.1093\/ndt\/gfp422.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"2366_CR10","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1046\/j.1523-1755.1999.00778.x","volume":"56","author":"DC Cattran","year":"1999","unstructured":"Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America nephrotic syndrome study group. Kidney Int. 1999;56(6):2220\u20136. https:\/\/doi.org\/10.1046\/j.1523-1755.1999.00778.x.","journal-title":"Kidney Int"},{"issue":"8","key":"2366_CR11","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/ki.2011.195","volume":"80","author":"DS Gipson","year":"2011","unstructured":"Gipson DS, Trachtman H, Kaskel FJ, Greene TH, Radeva MK, Gassman JJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int. 2011;80(8):868\u201378. https:\/\/doi.org\/10.1038\/ki.2011.195.","journal-title":"Kidney Int"},{"issue":"10","key":"2366_CR12","doi-asserted-by":"publisher","first-page":"e110376","DOI":"10.1371\/journal.pone.0110376","volume":"9","author":"M Yamaguchi","year":"2014","unstructured":"Yamaguchi M, Ando M, Yamamoto R, Akiyama S, Kato S, Katsuno T, et al. Patient age and the prognosis of idiopathic membranous nephropathy. PLoS\u00a0One. 2014;9(10):e110376. https:\/\/doi.org\/10.1371\/journal.pone.0110376.","journal-title":"PLoS\u00a0One."},{"issue":"8","key":"2366_CR13","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.2215\/CJN.10471013","volume":"9","author":"AP Bech","year":"2014","unstructured":"Bech AP, Hofstra JM, Brenchley PE, Wetzels JF. Association of anti-PLA(2)R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2014;9(8):1386\u201392. https:\/\/doi.org\/10.2215\/CJN.10471013.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2366_CR14","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1681\/ASN.2016070776","volume":"28","author":"AS De Vriese","year":"2017","unstructured":"De Vriese AS, Glassock RJ, Nath KA, Sethi S, Fervenza FC. A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol. 2017;28(2):421\u201330. https:\/\/doi.org\/10.1681\/ASN.2016070776.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2366_CR15","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s10157-014-1054-2","volume":"19","author":"S Akiyama","year":"2015","unstructured":"Akiyama S, Akiyama M, Imai E, Ozaki T, Matsuo S, Maruyama S. Prevalence of anti-phospholipase A2 receptor antibodies in Japanese patients with membranous nephropathy. Clin Exp Nephrol. 2015;19(4):653\u201360. https:\/\/doi.org\/10.1007\/s10157-014-1054-2.","journal-title":"Clin Exp Nephrol"},{"issue":"5","key":"2366_CR16","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1007\/s10157-013-0925-2","volume":"18","author":"T Saito","year":"2014","unstructured":"Saito T, Iwano M, Matsumoto K, Mitarai T, Yokoyama H, Yorioka N, et al. Significance of combined cyclosporine\u2212prednisolone therapy and cyclosporine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome: a randomized controlled multicenter trial. Clin Exp Nephrol. 2014;18(5):784\u201394. https:\/\/doi.org\/10.1007\/s10157-013-0925-2.","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"2366_CR17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000437288","volume":"1","author":"J Xu","year":"2015","unstructured":"Xu J, Hu X, Xie J, Chen N. Management of membranous nephropathy in Asia. Kidney Dis (Basel). 2015;1(2):119\u201325. https:\/\/doi.org\/10.1159\/000437288.","journal-title":"Kidney Dis (Basel)"},{"key":"2366_CR18","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.2147\/dddt.s204974","volume":"13","author":"S Lin","year":"2019","unstructured":"Lin S, Li H-Y, Zhou T, Lin W. Efficacy and safety of cyclosporine A in the treatment of idiopathic membranous nephropathy in an Asian population. Drug Des Devel Ther. 2019;13:2305\u201330. https:\/\/doi.org\/10.2147\/dddt.s204974.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"2366_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/nejmoa1814427","volume":"381","author":"FC Fervenza","year":"2019","unstructured":"Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med. 2019;381(1):36\u201346. https:\/\/doi.org\/10.1056\/nejmoa1814427.","journal-title":"N Engl J Med"},{"issue":"8","key":"2366_CR20","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1007\/s10157-021-02035-6","volume":"25","author":"M Kobayashi","year":"2021","unstructured":"Kobayashi M, Kageyama Y, Ando T, Sakamoto J, Kimura S. All-case Japanese post-marketing surveillance of the real-world safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome. Clin Exp Nephrol. 2021;25(8):854\u201364. https:\/\/doi.org\/10.1007\/s10157-021-02035-6.","journal-title":"Clin Exp Nephrol"},{"issue":"6","key":"2366_CR21","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/jjco\/hyac034","volume":"52","author":"J Eba","year":"2022","unstructured":"Eba J, Nakamura K. Overview of the ethical guidelines for medical and biological research involving human subjects in Japan. Jpn J Clin Oncol. 2022;52(6):539\u201344. https:\/\/doi.org\/10.1093\/jjco\/hyac034.","journal-title":"Jpn J Clin Oncol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-023-02366-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-023-02366-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-023-02366-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T02:04:20Z","timestamp":1692237860000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-023-02366-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["2366"],"URL":"https:\/\/doi.org\/10.1007\/s10157-023-02366-6","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,13]]},"assertion":[{"value":"23 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Honoraria: Hirokazu Okada (AstraZeneca, Daiichi Sankyo, Kyowa Kirin, Mitsubishi Tanabe Pharm, Torii Pharmaceutical), Noriaki Kurita (GlaxoSmithKline), Research funding: Kengo Furuichi (Chugai Pharmaceutical, Daiichi Sankyo), Hirokazu Okada (Kyowa Kirin), Subsidies or donations: Hirokazu Okada (Bayer, Chugai Pharmaceutical, Kyowa Kirin, Ono Pharmaceutical).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was an anonymous survey of healthcare professionals to describe the practice of primary nephrotic syndrome and was considered outside the scope of the ethical review according to the Ethical Guidelines for Medical and Biological Research Involving Human Subjects []. The possibility of academic publication of the survey results was described at the beginning of the questionnaire, and only those who provided consent to complete the survey were included.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}